A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.

@article{Faaborg2016A3E,
  title={A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.},
  author={Louise Faaborg and Isa Niemann and Eva Bjerre Ostenfeld and Estrid S Hansen and Lone E M Sunde and Jacob Chr Lindegaard},
  journal={Acta oncologica},
  year={2016},
  volume={55 2},
  pages={234-9}
}
BACKGROUND Treatment of postmolar gestational trophoblastic neoplasia (GTN) is often stratified according to FIGO score using methotrexate (MTX) for low-risk patients and first-line multi-agent chemotherapy (e.g. EMA-CO) for high-risk patients. In contrast, oral MTX may be given as first-line therapy to all GTN patients regardless of risk group. The aim was to examine the efficacy of oral MTX and a response-adapted treatment policy, which has been used for three decades at Aarhus University… CONTINUE READING